Stimuliver
Therapeutics
Read moreAPPLY FOR OUR PROGRAMS HERE
An international life science incubator in Copenhagen, Denmark
Start-ups
Start-ups
START-UPS: VENTURE LAB
The Venture Lab program combines business acceleration, scientific development and team development and is designed to help newly established start-ups within bioindustrials, health tech and therapeutics in the early phases. Venture Lab is for high-growth companies that have evidence-based ideas and must conduct key experiments to reach initial proof of concept, make a business plan and set a team that will allow them to progress rapidly towards the market.
Start-ups will each have a scientific advisor, a leadership coach and a BII anchor person that will closely follow the company’s development. The program comes with a EUR 500,000 risk-free convertible loan, a milestone plan to conduct key experiments and access to a unique global network of experts and life science VC’s.
Meet the Venture Lab start-ups below. Click on the start-up to read more.
Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list. Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.
ComMIT Biologics is a biotech spin-out from Aarhus University developing a new type of immunotherapy for the treatment of cancer. The company was founded on the discovery that the complement system – an important part of the innate immune system – can be potently directed to kill tumor cells using bi-specific single-domain antibodies. This discovery has been further refined into a new platform technology, that can be modified to efficiently target a variety of cancers.
HEI is a digital therapeutics company developing the world’s first medical-grade home monitoring solution for patients with hypothyroidism based on state-of-the-art microfluidics, microtechnology and artificial intelligence. The HEI solution is developed in close collaboration with patients and clinicians and empowers patients to better manage their condition by providing new digital opportunities for continuous care. More than 200 million people suffer from hypothyroidism globally and a large group of patients are undiagnosed or not properly medicated, leading to decreased quality of life, impaired job readiness, and elevated risks of comorbidities and mortality.
EvodiaBio is a bio-industrial company producing sustainable, natural aromas for the food and beverage industry. Our disruptive yeast-based technology enables consumers to enjoy the benefits of non-alcoholic beer without having to compromise on taste. Read more on http://evodiabio.com/
FLASH diagnostics brings cutting-edge microscopy developments to the clinical diagnosis of cancer patients. Optical tissue clearing in combination with high-speed imaging identifies metastasizing tumor cells in large intact tissue volumes. We employ three-dimensional screening of entire cancer resections to enable the absolute quantification of cancer spread and precise patient staging.
Bioomix develops new microbial solutions that can replace fungicides, synthetic fertilizers and antibiotics. Our approach is based on a 3D printed discovery platform that uses natural selection and synthetic ecology to capture microbes with beneficial properties. Our vision is to reduce microbial resistance and pollution and to make food production more sustainable.
Ampa Medical is introducing a new solution for collecting output from ostomies that is radically different than the current solution – the stoma bag. We wish to remove time-consuming, mental and physical obstacles related to the current use of stoma bags. By this, we hope to make a new and better life for persons who live with a stoma.
START-UPS: CREATION HOUSE
The Creation House program provides funding of up to EUR 1,3M (DKK 10M). As part of the program, your start-up team can relocate to BII in Copenhagen and will work intensively towards the primary objective of bringing the project to a stage to attract funding (e.g. series A) to support further development and/or growth.
During the time in the Creation House program, BII will provide the support needed for your team to succeed.
Meet the Creation House start-ups below. Click on the start-up to read more.
Embark Biotech is a spin-out from the University of Copenhagen with the aim of pioneering novel drugs for metabolic diseases. Embark’s first program focuses on proprietary agonists to a novel receptor (EMB1), identified by our in-house discovery platform. EMB1 agonists act on adipose cells to absorb and burn sugar and fat, and centrally to reduce food intake. EMB1 has potential in several metabolic diseases, including type 2 diabetes, obesity and genetic forms of obesity such as Prader-Willi Syndrome. The main objective in Embark is to advance the development of an EMB1 agonist within Prader-Willi Syndrome.
The largest unmet need for nearly all genetic forms of obesity is the uncontrolled desire to eat (i.e. hyperphagia). Embark seeks to make a breakthrough in this area by introducing a first-in-class drug countering hyperphagia in the most common form of genetic obesity, Prader-Willi Syndrome (PWS).
PWS is an orphan disease characterized by intense hyperphagia, decreased metabolic rate and progressive weight gain accompanied by an increased risk of severe obesity, diabetes and related complications. Currently, no treatment for PWS hyperphagia exists. Embark has developed agonists for a novel receptor, EMB1, which profoundly decreases food intake and improves metabolic health in hyperphagic mouse models and obese, diabetic non-human primates. We expect that further preclinical development in PWS models will specifically reveal its potential for PWS.
iNotify focuses on the initial ovarian follicle development to help infertile women who are not benefitting from today’s standard hormone treatment. The company uses first-in-class drug-inducing factors that regulated the intracellular AKT pathway; a major driver of follicle activation and a signal transductive pathway that promotes survival and growth in response to extracellular signals. The company has identified and validated a compound that activates the AKT pathway in a controlled manner, and thus supports the activation of dormant follicles, a pre-request for fertility.
Harnessing sensor and AI technologies, Orbit Health provides doctors with continuous and objective insights to enable effective personalized treatment and continuous management of chronic patients at home.
The company’s first solution, Neptune, is an AI solution that uses only a smartwatch to enable treatment optimization to help people with Parkinson’s attain optimal symptom control and restore quality of life. In addition, Orbit Digital Health Lab enables the orchestration of an array of relevant digital health solutions to be applied to a single patient. Orbit brings these solutions from their siloed environment and integrates them into the routine clinical workflow to achieve holistic patient care and real impact.
Our vision is to truly enable early intervention and cost-effective management of chronic conditions by offering breakthrough digital health solutions to enable physicians to tailor and optimize care and empower patients to live their best possible lives.
Pephexia Therapeutics is a biotechnology company working with the discovery and development of innovative peptide-based pharmacotherapies for the effective and convenient treatment of cachexia and related diseases.
Sundew, formed in 2018, is a Danish-Dutch start-up biological technology venture focused on developing a range of biology-based technology platforms that enable the development of effective, affordable, environmentally benign products targeted at aquatic pests and diseases. Sundew is headquartered in Copenhagen (www.sundew.bio).
Ciana Therapeutics is a clinical development-stage company led by an experienced team developing new therapies for diabetic retinopathy (DR). DR is a serious condition that afflicts 30% of patients with diabetes and leads to vision loss and blindness. Ciana is a spin-out from Zealand Pharma A/S that originally developed their lead drug therapy, Danegaptide. Danegaptide has a proven safety profile in humans, strong efficacy in pre-clinical DR models and can uniquely address the need for more effective and earlier treatments in DR. Learn more about Ciana Therapeutics on www.cianatx.com
2N Pharma is developing a disease-modifying new drug for the treatment of amyotrophic lateral sclerosis (ALS) and is building its case on 10 years of research led by Co-founder John Nieland. The participation in the Creation House program will allow 2N to optimise its lead molecules and take significant steps towards clinical testing. Read more on https://2npharma.com/
Learn more about 2N Pharma here
PokeAcell is developing personalized T cell therapies to late stage solid tumors. T cells are the elite soldiers of our immune system and have the capacity to create lasting response in solid tumor patients. PokeAcell’s ImmPACT technology mimic the natural stimulation of cancer specific T cells, outside the patients body, and create a strong, safe and simple T cell product for Melanoma and Merkel Cell Carcinoma. With PokeAcell’s insight to cancer antigens, the approach can be expanded to other cancers creating a new platform for T cell therapy.
Learn more about PokeAcell here
Follow them on LinkedIn
Or read about them in this article:
UNIKUM is working on pDC’s – uniquely transforming Immunotherapy.
Read more about UNIKUM in this news article: DKK 10 M for life science project from Aarhus University
Bainan Biotech is developing a first-in-class bone-strengthening drug. The drug’s effect arises from boosting the body’s naturally occurring bone-strengthening response to a healthy meal. Not only nutrition and minerals in the food but also the body’s hormonal response to eating is very important for maintaining strong and healthy bones. Bainan Biotech’s drug stimulates the body’s bone-strengthening hormonal response to eating as a new way of treating osteoporosis.
Learn more about Bainan Biotech here
Follow them on LinkedIn
Twelve Bio uses state-of-the-art techniques in structural biology to manipulate and improve the abilities of CRISPR-Cas12a to recognized and cleave specific DNA sequences. Our goal is to obtain new CRISPR-Cas12a variants that can be safely used in gene-editing for therapeutical purposes. Twelve Bio is the first spin-out company from the NNF Center of protein Research where we obtained the first “movie” on how Cas12a moves from the recognition to the cleavage of the specific DNA target.
Learn more about Twelve Bio here
Follow them on LinkedIn
Or read about them in this article:
Meet the start-ups: Twelve Bio
START-UPS: BUSINESS ACCELERATION
Research project from the University of Copenhagen run by Professor Thue W. Schwarts and his team. Working on antagonists for the Lactate Receptor GPR81/ HCAR1 for Treatment of Solid Tumours
Research project from The University of Copenhagen run by Professor Anders Miki Bojesen and his team. Working on a vaccine manufacturing technique for large-scale production of bacterial outer membrane vesicles (OMVs)
Start-up company founded by Martin Blomberg Jensen and based on research from Rigshospitalet. It is a first in class treatment for male infertility.
Making biobased production possible at any scale by self-selecting fermentations. Read more about Enduro Genetics.
A novel therapeutic approach for treatment of obesity.
Working on this is Professor Christoffer Clemmensen and his team from Copenhagen University.
KT
KT
Kesmalea Therapeutics is a British start-up, founded by Harry Finch. They are working on accelerating the discovery of novel protein degraders and providing an alternative approach for therapeutics with ‘PROTAC-like’ actions.
Read more about their research here.
BOOST cells (in vitro expanded mesenchymal stem cells) are developed to treat severe Osteogenesis Imperfecta (OI) or Brittle Bone Disease in children and unborn babies. OI is an inherited severely handicapping disease, that leads to e.g. multiple fractures, short body stature and pain.
BOOST Pharma believes that treating early before too much damage has occurred is beneficial. In an academic setting, they have previously treated four children and have demonstrated that the BOOST cells are safe and potentially effective. In an academic Horizon 2020-funded ongoing clinical phase I/II study, safety and efficacy in a larger patient group is investigated.
Learn more about BOOST Pharma here
Or read more about them in this article:
Meet the therapeutics start-up: BOOST Pharma
ALUMNI: CREATION HOUSE
Meet the Creation House alumni below and read the interview with of one of the first companies that joined BII in 2018: From Associate Professor to CSO with a series A investment
Teitur Trophics is working on small peptides acting on the Sortilin family that is involved in neurogenerative diseases like Huntington’s, Alzheimer’s and Parkinson’s disease.
Follow them on LinkedIn
Or read about them in this article:
Lophora develops rapid acting drugs for treatment-resistant depression.
Lophora is developing an antidepressant with a novel mode of action that has the potential to work within days. The company has identified and patented a new class of proprietary ligands that has a similar pharmacological profile as psilocybin, which has shown promising clinical results in the treatment of depression. Lophora is currently focusing on Treatment-Resistant Depression, but clinical data suggests that the novel treatment paradigm will be applicable to the treatment of anxiety, PTSD and substance abuse.
Lophora was formerly part of the BII Business Acceleration Academy
Learn more about Lophora here
Follow them on LinkedIn
Or read about them in these articles:
BAA alumni funded with DKK 10M in Creation House
Dedicated to improving life quality for millions of people suffering from diabetes, Pancryos is developing a next generation stem cell derived cell therapy PanINSULA. This is a stem cell-based cell therapy to replace the damaged insulin-producing beta cells that are mistakenly destroyed during the autoimmune disease type 1 diabetes.
Learn more about Pancryos here
Follow them on LinkedIn
Or read about them in this article:
Kariya Pharmaceuticals is developing first-in-class disease modifying agents to treat neurodegenerative diseases.
Learn more about Kariya Pharmaceuticals here
Follow them on LinkedIn
Or read about them in thesse articles:
Inprother is an immunotherapy company dedicated to developing the world’s first adaptive immune therapy capable of targeting immunosuppressive genes of ancient retroviruses that normally are dormant in the human genome. The retroviral genes are reactivated in cancer and essential for tumor development. InProTher’s proprietary combination of novel technologies is designed to break tolerance to this unique antigen family, thus providing broad anti-cancer efficacy.
InProTher was formerly part of the BII Business Acceleration Academy.
Learn more about InProTher here
Follow them on LinkedIn
Or read about them in these articles:
BII start-up attracts corporate profile as CEO
Catching up with three BAA alumni start-ups
Two start-ups accepted in the Creation House program
Cirqle Biomedical has developed an innovative contraceptive for women, without the many side effects of hormonal birth control. This product makes cervical mucus temporarily impenetrable to sperm. The barrier is established by a molecule that strongly interacts with cervical mucus and thereby reinforce the mucus to make it impenetrable for sperm cells. Sperm cells are trapped in the cervical mucus and maintained in the vaginal cavity where the low pH environment of the vagina deactivates them.
Cirqle was formerly part of the BII Business Acceleration Academy, and the Creation House program.
Learn more about Cirqle Biomedical here
Follow them on LinkedIn
Or read about them in these articles:
Ankrin Therapeutics is a biotech start-up developing first-in-class drugs for cancer treatment. Their novel and unique therapeutic strategies, founded on forefront high quality research in cancer biology, target essential protein-protein interactions required for error-free DNA damage repair.
Learn more about Ankrin Therapeutics here
Follow them on LinkedIn
Or read about them in this article:
ALUMNI: BUSINESS ACCELERATION ACADEMY
Meet the Business Acceleration Academy alumni below. Click on the start-up to read more and learn more about our new acceleration program Venture Lab.
BOOST cells (in vitro expanded mesenchymal stem cells) are developed to treat severe Osteogenesis Imperfecta (OI) or Brittle Bone Disease in children and unborn babies. OI is an inherited severely handicapping disease, that leads to e.g. multiple fractures, short body stature and pain.
BOOST Pharma believes that treating early before too much damage has occurred is beneficial. In an academic setting, they have previously treated four children and have demonstrated that the BOOST cells are safe and potentially effective. In an academic Horizon 2020-funded ongoing clinical phase I/II study, safety and efficacy in a larger patient group is investigated.
Learn more about BOOST Pharma here
Or read more about them in this article:
Meet the therapeutics start-up: BOOST Pharma
SecondCircle, biotech: Secondcircle is transforming CO2 into business opportunities. The company is developing disruptive carbon capture and utilization technology (CCU) that converts CO2 into valuable products, including biochemicals and proteins. The solution is based on a novel approach for fixating CO2 using bacteria, which reduces the operating and establishment costs significantly. SecondCircle provides value to companies that are ready for a greener future.
Read more about them in this article:
Meet the bio-industrial start-up: SecondCircle
Fertilitypro, pharma: FertilityPro is developing a first-in-class therapy for male infertility. The company was founded in 2020 and based on more than ten years of research in the endocrine crosstalk between the skeleton and the reproductive system.
Infertility affects 15% of all couples globally, and despite that, a malefactor responsible in 40% of cases, we exclusively treat the woman for a male disease with hormonal and invasive therapy. Our discovery of the RANKL-signaling system in the human testis has opened a pathway for a new paradigm where male infertility can be treated by treating the males with a RANKL inhibitor.
FertilityPro is currently repurposing the use of RANKL-inhibitors as a treatment for male infertility based on the company’s second medical patent and a patent on companion diagnostics to select the men that will benefit from the treatment. FertilityPro provides solutions for building families.
Ward 24/7 is an early stage health tech company aiming to predict and prevent critical clinical events in hospital wards by transforming patient monitoring practice and technology. Based on 24/7, wireless vital sign monitoring, Ward 24/7 develop artificially intelligent algorithms that use machine learning to generate new medical knowledge.
The technology can help recognize clinical deterioration early enough to prevent unexpected and often fatal or very critical events such as stroke and sepsis.
Read more about them in this article:
Chromologics is a Danish biotech company developing fungal fermentation solutions for the production of novel, natural pigments. Using our proprietary fungal fermentation process, we can produce pigments cost-competitively in a sustainable manner compared to existing natural colors which are extracted in low yields from food sources. Our fungal strains are non-GMO and our pigments are compatible with most dietary needs, including kosher, halal, and vegan diets.
Read more about Chromologics here
Or in this article with co-founder Gerit Tolborg.
Bifrost Biolabs makes biology easier by creating laboratory automation for the biotech industry, creating a novel high throughput sensor system that can give the user a high-quality biomass measurement to aid in the optimization of any fermentation process.
Learn more about Bifrost Biolabs here
Follow them on LinkedIn
Or read about them in this article:
Octarine harnesses synthetic biology to develop functionally superior cannabinoid and psilocybin derivatives.
Using their unique biosynthetic platform they engineer microorganisms to produce a range of natural and novel cannabinoid and psilocybin derived molecules with improved pharmacokinetic and therapeutic properties.
Learn more about Octarine here
Follow them on LinkedInOr read about them in this article:
prOxi biotech develops a BACTOVAC platform, overcoming main barriers of traditional vaccine developing technologies allowing for new, highly needed vaccines to enter the market and fight multi-resistant bacteria.
Learn more about prOxi biotech here
Follow them on LinkedIn
Or read about them in these articles:
atSpiro makes biotechnology research faster and more efficient by digitizing early stages of the strain screening pipeline – adding automatic control and collecting data at an unprecedented scale.
The current, industry-standard strain screening process consists of several stages. One of which relies on shaker flasks and cotton balls – this is a weak link in an otherwise highly-developed and technical operation. At this stage, hundreds of experiments run in parallel, and potentially valuable strains are lost due to error-based changes in their environments. atSpiro industry-disrupting product will enhance analysis of these strains to optimize the environments for future strains being screened.
Learn more about atSpiro here
Follow them on LinkedIn
Or read about them in this article:
Mycropt offers tailored solutions for biotech, biopharma and research companies that wants to improve their protein production or diversify their product portfolio.
They apply a unique platform technology to help customers enable the production of novel, difficult-to-express targets and enhance the yield of existing products.
Learn more about Mycropt here
Follow them on LinkedIn
Or read about them in these articles:
Heart View Medical works with high-speed three dimensional echocardiology, for improved accuracy of irregularities in the heart.
Currently there are limitations to existing imaging methods in their ability to rapidly record cardiac events (at physiologic speeds). In the case of 3D echo, CT and MRI, the problem is further confounded by the necessity to create images over multiple heartbeats where only portions of the image are obtained in a single heartbeat. Because of current slow imaging rates, it is likely that certain cardiac abnormalities remain undetectable.
Echocardiography would improve the understanding of arrhythmia development for electrophysiology procedures and shorten procedure time and minimize patient risk.
Learn more about Heart View Medical here
Follow them on LinkedIn
Fermbiotics is a company developing natural fermented seaweed and plant products that support gut health.
They produce fermented plant and seaweed products as food ingredients, dietary supplements and medical foods by combining prebiotics, probiotics and bioactive compounds. This has resulted in a new category of fermented food ingredients and dietary supplements for both humans and animals, which can stimulate a positive gut microbiome (gut microflora).
Learn more about FermBiotics here
Follow them on LinkedIn
Or read about them in this article:
Bainan Biotech is developing a first-in-class bone-strengthening drug. The drug’s effect arises from boosting the body’s naturally occurring bone-strengthening response to a healthy meal. Not only nutrition and minerals in the food but also the body’s hormonal response to eating is very important for maintaining strong and healthy bones. Bainan Biotech’s drug stimulates the body’s bone-strengthening hormonal response to eating as a new way of treating osteoporosis.
Learn more about Bainan Biotech here
Follow them on LinkedIn
MedicQuant’s vision is to enable rapid and local tests for anticoagulants at the point-of-care to benefit patients. Currently, there is no readily available solutions to address blood levels of the anticoagulants called Direct Oral Anticoagulants (DOACs) at the point-of-care. MedicQuant have developed a novel technology, chip and instrument that can detect DOACs, directly from whole blood within only 10 minutes. The elegant simplicity of our solution will provide a readily available test to use at individual departments at all hospitals.
Learn more about MedicQuant here
Follow them on LinkedIn
Or read about them in these articles:
iBio tech advances diagnostic solutions and therapies for autoimmune diseases, aiming to benefit patients while creating a successful business.
Learn more about them here
Or read about them in this article:
Twelve Bio uses state-of-the-art techniques in structural biology to manipulate and improve the abilities of CRISPR-Cas12a to recognized and cleave specific DNA sequences. Our goal is to obtain new CRISPR-Cas12a variants that can be safely used in gene-editing for therapeutical purposes. Twelve Bio is the first spin-out company from the NNF Center of protein Research where we obtained the first “movie” on how Cas12a moves from the recognition to the cleavage of the specific DNA target.
Learn more about Twelve Bio here
Follow them on LinkedIn
Or read about them in this article:
Meet the start-ups: Twelve Bio
Metabolyzer represents the next step in human gut microbiome analysis. We are developing a range of services that will provide precise metabolic insights on the basis of amplicon or shotgun metagenome sequencing data. Based on more than twenty years of research, our digital metabolism approach translates the microbial crosstalk on a molecular level enabling a mechanistic understanding of the processes underlying an individual’s response to pre-biotics and changes in diet. We are primarily targeting human gut microbiome businesses who want to make sure that they get the most of their data.
Learn more about Metabolyzer here
Or read about them in this article:
RESIDENTS
BII houses resident companies that rent access to the lab and office space on market terms. Feel free to contact BII’s Lab Manager Bo Heinemann for inquiries about renting lab and office space at BioInnovation Institute.
Meet the BII resident companies below. Click on the start-up to read more.
Hemab ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licenses to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab.
Fermexa is a world class innovator in the field of pharmaceuticals based on polyphenols with a strong emphasis on flavonoids. Fermexa is creating a range of cutting-edge technologies for synthetic optimization of polyphenols, e.g. by fermentation as the company name implies. Fermexa is currently developing commercially scalable productions in close cooperation with global partners.
Blue Cell Therapeutics (RT) is an innovative Danish company that seeks to create value for patients, partners, employees and investors by developing new stem/progenitor cell products and medical devices technologies for chronic diseases, to make Blue Cell therapy a global reference within regenerative medicine. RT’s vision is to introduce freshly isolated and cultured Blue Cell treatments as the gold standard in hospitals and clinics worldwide for the treatment of conditions such as erectile dysfunction, lymphedema and fistulas in Crohn’s disease.
Bainan Biotech is developing a first-in-class bone-strengthening drug. The drug’s effect arises from boosting the body’s naturally occurring bone-strengthening response to a healthy meal. Not only nutrition and minerals in the food but also the body’s hormonal response to eating is very important for maintaining strong and healthy bones. Bainan Biotech’s drug stimulates the body’s bone-strengthening hormonal response to eating as a new way of treating osteoporosis.
Learn more about Bainan Biotech here
Follow them on LinkedIn
Finding a better way to help organ or stem cell transplant recipients recover from transplantation, by developing a cure for frequent CMV infections. Their drug candidate SYNx is a highly effective, potent, and fast-acting CMV-specific immunotoxin with the unique ability to kill lytic and latently infected cells. Its unique mechanism allows for stand-alone and combination therapy. Their technology will pave the way to better patient health and better transplant economy.
Learn more about Synklino here
Follow them on LinkedIn
Or read about them in this article:
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.
In 2019, STipe Therapeutics raised a series A investments of 20M DKK. Read the story here: Creation House company raises series a invetment.
Read more about STipe Therapeutics here: stipetherapeutics.com
Inprother is an immunotherapy company dedicated to developing the world’s first adaptive immune therapy capable of targeting immunosuppressive genes of ancient retroviruses that normally are dormant in the human genome. The retroviral genes are reactivated in cancer and essential for tumor development. InProTher’s proprietary combination of novel technologies is designed to break tolerance to this unique antigen family, thus providing broad anti-cancer efficacy.
InProTher was formerly part of the BII Business Acceleration Academy.
Learn more about InProTher here
Follow them on LinkedIn
Or read about them in these articles:
BII start-up attracts corporate profile as CEO
Catching up with three BAA alumni start-ups
Two start-ups accepted in the Creation House program
Cirqle Biomedical has developed an innovative contraceptive for women, without the many side effects of hormonal birth control. This product makes cervical mucus temporarily impenetrable to sperm. The barrier is established by a molecule that strongly interacts with cervical mucus and thereby reinforce the mucus to make it impenetrable for sperm cells. Sperm cells are trapped in the cervical mucus and maintained in the vaginal cavity where the low pH environment of the vagina deactivates them.
Cirqle was formerly part of the BII Business Acceleration Academy, and the Creation House program.
Learn more about Cirqle Biomedical here
Follow them on LinkedIn
Or read about them in these articles:
Ankrin Therapeutics is a biotech start-up developing first-in-class drugs for cancer treatment. Their novel and unique therapeutic strategies, founded on forefront high quality research in cancer biology, target essential protein-protein interactions required for error-free DNA damage repair.
Learn more about Ankrin Therapeutics here
Follow them on LinkedIn
Or read about them in this article:
Adcendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Learn more about Adcendo here
Follow them on LinkedIn
Or read about them in these articles:
Start-up job portal
Do you aspire to become part of a life science start-up on their journey towards consolidating their company and finding new solutions to cope with some of society’s most pressing challenges? Then use our Talent Recruitment Portal and apply for a position at one of the life science start-ups in BII’s community that you believe suits your profile.